From: IGF-1 in Friedreich’s Ataxia – proof-of-concept trial
FRDA patients
N
Annual worsening rate
CI 95%
Baseline – 3rd four-month period (AWR)
5
-0.40 ± 0.83
-1.28 to 0.48
Control
99
2,05 ± 1,23
1,58 to 2,52